ZVRA
Zevra Therapeutics, Inc.
Price Chart
Latest Quote
$10.61
-0.56 (-5.01%)
Current Price
| Previous Close | $11.17 |
| Open | $11.14 |
| Day High | $11.18 |
| Day Low | $10.36 |
| Volume | 2,115,757 |
Stock Information
| Shares Outstanding | 59.12M |
| Total Debt | $1.15M |
| Cash Equivalents | $200.62M |
| Revenue | $122.29M |
| Net Income | $117.00M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $627.21M |
| P/E Ratio | 5.28 |
| EPS (TTM) | $2.01 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $460.85M |
| Sales | $122.29M |
| Income | $117.00M |
| Book/sh | $3.48 |
| Cash/sh | $3.39 |
| Employees | 61 |
Financial Ratios
| Quick Ratio | 4.74 |
| Current Ratio | 4.89 |
| Debt/Eq | 0.56 |
Returns & Margins
| ROA | 2.76% |
| ROE | 100.65% |
| Gross Margin | 86.07% |
| Operating Margin | 24.38% |
| Profit Margin | 101.58% |
Ownership
| Insider Ownership | 1.40% |
| Institutional Ownership | 70.73% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 5.54 |
| PEG | 10.67 |
| P/S | 5.13 |
| P/B | 3.05 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $23.00 |
Technical Indicators
| SMA20 | $10.88 |
| SMA50 | $10.33 |
| SMA200 | $9.43 |
| RSI | 45.73 |
| ATR | 0.5671 |
| Shares Float | 54.96M |
| Short Float | 7.60% |
| Short Ratio | 3.48 |
| Volatility | 0.89 |
| Rel Volume | 1.05 |
Performance History
| Week | -8.46% |
| Month | -5.69% |
| Quarter | +18.15% |
| 6 Months | +21.67% |
| YTD | +27.22% |
| Year | +18.55% |
| 3 Years | +110.52% |
| 5 Years | +3.61% |
| 10 Years | -91.25% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $10.61 | 2,115,757 |
| 2026-06-04 | $11.17 | 949,600 |
| 2026-06-03 | $10.96 | 1,583,400 |
| 2026-06-02 | $10.88 | 1,816,200 |
| 2026-06-01 | $11.49 | 2,054,900 |
| 2026-05-29 | $11.59 | 2,257,300 |
| 2026-05-28 | $11.40 | 3,288,000 |
| 2026-05-27 | $10.95 | 2,687,500 |
| 2026-05-26 | $10.32 | 1,853,200 |
| 2026-05-22 | $10.03 | 1,364,000 |
| 2026-05-21 | $10.49 | 2,441,200 |
| 2026-05-20 | $10.24 | 1,028,800 |
| 2026-05-19 | $10.20 | 2,541,500 |
| 2026-05-18 | $10.43 | 2,285,200 |
| 2026-05-15 | $11.01 | 1,728,100 |
| 2026-05-14 | $11.66 | 3,090,800 |
| 2026-05-13 | $11.12 | 1,019,200 |
| 2026-05-12 | $11.05 | 1,122,200 |
| 2026-05-11 | $10.80 | 2,235,100 |
| 2026-05-08 | $11.13 | 2,650,200 |
| 2026-05-07 | $11.00 | 2,628,900 |
| 2026-05-06 | $11.25 | 2,072,000 |
About Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
đ° Latest News
Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear
Simply Wall St. âĸ 2026-05-13T11:22:01Z
Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Simply Wall St. âĸ 2026-05-09T14:15:13Z
Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?
Simply Wall St. âĸ 2026-05-07T18:19:04Z
Zevra Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-07T10:07:10Z
Zevra Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-07T00:31:59Z
Zevra (ZVRA) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-05-06T22:45:52Z
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
Zacks âĸ 2026-05-06T22:30:20Z
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-05T13:15:06Z
Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage?
Simply Wall St. âĸ 2026-03-24T01:07:17Z
Zevra Ties NPC Testing Push To Valuation Gap And New CFO
Simply Wall St. âĸ 2026-03-23T01:05:45Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $16,290,000 | $7,263,000 | $1,939,000 | $222,000 |
| Cost Of Revenue | $16,482,000 | $7,417,000 | $2,173,000 | $222,000 |
| Total Revenue | $106,470,000 | $23,612,000 | $27,461,000 | $10,161,000 |
| Operating Revenue | $106,470,000 | $23,612,000 | $27,461,000 | $10,161,000 |
| Expenses | ||||
| Interest Expense | $7,977,000 | $7,351,000 | $1,501,000 | $335,000 |
| Total Expenses | $110,703,000 | $110,615,000 | $77,065,000 | $35,063,000 |
| Other Income Expense | $91,942,000 | $2,039,000 | $515,000 | $-3,081,000 |
| Net Non Operating Interest Income Expense | $-1,031,000 | $-5,176,000 | $3,040,000 | $1,178,000 |
| Interest Expense Non Operating | $7,977,000 | $7,351,000 | $1,501,000 | $335,000 |
| Operating Expense | $94,221,000 | $103,198,000 | $74,892,000 | $34,841,000 |
| General And Administrative Expense | - | - | - | $15,343,000 |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $83,229,000 | $-105,511,000 | $-46,049,000 | $-26,772,000 |
| Net Interest Income | $-1,031,000 | $-5,176,000 | $3,040,000 | $1,178,000 |
| Interest Income | $6,946,000 | $2,175,000 | $4,541,000 | $1,513,000 |
| Normalized Income | $-5,053,708 | $-107,121,810 | $-46,564,000 | $-23,694,697 |
| Net Income From Continuing And Discontinued Operation | $83,229,000 | $-105,511,000 | $-46,049,000 | $-26,772,000 |
| Total Operating Income As Reported | $-62,943,000 | $-87,003,000 | $-49,604,000 | $-42,565,000 |
| Net Income Common Stockholders | $83,229,000 | $-105,511,000 | $-46,049,000 | $-26,772,000 |
| Net Income | $83,229,000 | $-105,511,000 | $-46,049,000 | $-26,772,000 |
| Net Income Including Noncontrolling Interests | $83,229,000 | $-105,511,000 | $-46,049,000 | $-26,772,000 |
| Net Income Continuous Operations | $83,229,000 | $-105,511,000 | $-46,049,000 | $-26,772,000 |
| Pretax Income | $86,678,000 | $-90,140,000 | $-46,049,000 | $-26,805,000 |
| Special Income Charges | $89,615,000 | $0 | $0 | $-17,663,000 |
| Interest Income Non Operating | $6,946,000 | $2,175,000 | $4,541,000 | $1,513,000 |
| Operating Income | $-4,233,000 | $-87,003,000 | $-49,604,000 | $-24,902,000 |
| Depreciation Amortization Depletion Income Statement | $3,862,000 | $6,235,000 | $772,000 | - |
| Depreciation And Amortization In Income Statement | $3,862,000 | $6,235,000 | $772,000 | - |
| Amortization Of Intangibles Income Statement | $3,862,000 | $6,235,000 | $772,000 | - |
| Gross Profit | $89,988,000 | $16,195,000 | $25,288,000 | $9,939,000 |
| Per Share | ||||
| Diluted EPS | $1.35 | $-2.28 | $-1.30 | $-1.20 |
| Basic EPS | $1.40 | $-2.28 | $-1.30 | $-1.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $3,659,292 | $428,190 | $0 | $-3,697 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $6,767,000 | $-78,439,000 | $-44,057,000 | $-22,445,000 |
| Total Unusual Items | $91,942,000 | $2,039,000 | $515,000 | $-3,081,000 |
| Total Unusual Items Excluding Goodwill | $91,942,000 | $2,039,000 | $515,000 | $-3,081,000 |
| Reconciled Depreciation | $4,054,000 | $6,389,000 | $1,006,000 | $944,000 |
| EBITDA (Bullshit earnings) | $98,709,000 | $-76,400,000 | $-43,542,000 | $-25,526,000 |
| EBIT | $94,655,000 | $-82,789,000 | $-44,548,000 | $-26,470,000 |
| Diluted Average Shares | $57,262,715 | $46,251,239 | $35,452,460 | $34,488,800 |
| Basic Average Shares | $55,311,308 | $46,251,239 | $35,452,460 | $34,488,800 |
| Diluted NI Availto Com Stockholders | $83,229,000 | $-105,511,000 | $-46,049,000 | $-26,772,000 |
| Tax Provision | $3,449,000 | $15,371,000 | $0 | $-33,000 |
| Gain On Sale Of Ppe | $148,325,000 | $0 | - | - |
| Impairment Of Capital Assets | $58,710,000 | $0 | - | - |
| Gain On Sale Of Security | $2,327,000 | $2,039,000 | $515,000 | $14,582,000 |
| Amortization | $3,862,000 | $6,235,000 | $772,000 | - |
| Research And Development | $12,743,000 | $42,095,000 | $39,806,000 | $19,803,000 |
| Selling General And Administration | $77,616,000 | $54,868,000 | $34,314,000 | $15,038,000 |
| Otherunder Preferred Stock Dividend | - | - | - | $0 |
| Other Special Charges | - | - | - | $17,663,000 |
| Other Gand A | - | - | - | $15,343,000 |
| Restructuring And Mergern Acquisition | - | - | - | - |
Fetched: 2026-06-01
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $143,535,000 | $-34,028,000 | $-12,064,000 | $75,120,000 |
| Total Assets | $284,731,000 | $178,127,000 | $172,327,000 | $115,340,000 |
| Total Non Current Assets | $61,724,000 | $92,100,000 | $85,389,000 | $22,506,000 |
| Other Non Current Assets | $1,022,000 | $11,383,000 | $9,935,000 | $724,000 |
| Investmentin Financial Assets | $47,879,000 | $6,010,000 | $0 | $0 |
| Goodwill And Other Intangible Assets | $11,122,000 | $73,694,000 | $73,928,000 | $0 |
| Other Intangible Assets | $6,421,000 | $68,993,000 | $69,227,000 | - |
| Current Assets | $223,007,000 | $86,027,000 | $86,938,000 | $92,834,000 |
| Other Current Assets | $6,052,000 | $3,015,000 | $652,000 | $1,111,000 |
| Prepaid Assets | $946,000 | $1,037,000 | $1,172,000 | $577,000 |
| Inventory | $1,740,000 | $1,970,000 | $0 | - |
| Receivables | $23,258,000 | $10,509,000 | $17,377,000 | $8,299,000 |
| Other Receivables | $13,382,000 | $6,499,000 | $1,258,000 | $1,114,000 |
| Accounts Receivable | $9,876,000 | $4,010,000 | $16,119,000 | $7,185,000 |
| Cash Cash Equivalents And Short Term Investments | $191,011,000 | $69,496,000 | $67,737,000 | $82,847,000 |
| Cash And Cash Equivalents | $62,406,000 | $33,785,000 | $43,049,000 | $65,466,000 |
| Restricted Cash | - | - | - | - |
| Debt | ||||
| Total Debt | $63,206,000 | $60,296,000 | $43,765,000 | $14,123,000 |
| Long Term Debt And Capital Lease Obligation | $62,787,000 | $59,876,000 | $5,522,000 | $13,643,000 |
| Long Term Debt | $61,928,000 | $59,504,000 | $5,066,000 | $12,800,000 |
| Current Debt And Capital Lease Obligation | $419,000 | $420,000 | $38,243,000 | $480,000 |
| Net Debt | - | $25,719,000 | - | - |
| Current Debt | - | - | $37,700,000 | $4,655,000 |
| Other Current Borrowings | - | - | $37,700,000 | $4,655,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $130,074,000 | $138,461,000 | $110,463,000 | $40,220,000 |
| Total Non Current Liabilities Net Minority Interest | $90,797,000 | $104,396,000 | $36,743,000 | $28,197,000 |
| Other Non Current Liabilities | $11,406,000 | $12,285,000 | $15,121,000 | $4,352,000 |
| Derivative Product Liabilities | $9,575,000 | $17,804,000 | $16,100,000 | $10,202,000 |
| Tradeand Other Payables Non Current | $7,029,000 | $14,431,000 | $0 | - |
| Current Liabilities | $39,277,000 | $34,065,000 | $73,720,000 | $12,023,000 |
| Other Current Liabilities | $13,550,000 | $8,189,000 | $7,074,000 | $5,374,000 |
| Payables And Accrued Expenses | $25,308,000 | $25,456,000 | $28,403,000 | $6,169,000 |
| Payables | $16,188,000 | $13,075,000 | $13,987,000 | $3,611,000 |
| Total Tax Payable | $13,710,000 | $0 | - | - |
| Income Tax Payable | $13,710,000 | $0 | - | - |
| Accounts Payable | $2,478,000 | $13,075,000 | $13,987,000 | $3,611,000 |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $154,657,000 | $39,666,000 | $61,864,000 | $75,120,000 |
| Total Equity Gross Minority Interest | $154,657,000 | $39,666,000 | $61,864,000 | $75,120,000 |
| Stockholders Equity | $154,657,000 | $39,666,000 | $61,864,000 | $75,120,000 |
| Gains Losses Not Affecting Retained Earnings | $-764,000 | $631,000 | $-43,000 | $113,000 |
| Other Equity Adjustments | $-764,000 | $631,000 | $-43,000 | $113,000 |
| Retained Earnings | $-422,060,000 | $-505,289,000 | $-399,778,000 | $-353,729,000 |
| Other | ||||
| Treasury Shares Number | $1,483,538 | $1,575,692 | $1,575,692 | $909,953 |
| Ordinary Shares Number | $56,854,781 | $53,670,709 | $41,534,668 | $34,540,304 |
| Share Issued | $58,338,319 | $55,246,401 | $43,110,360 | $35,450,257 |
| Tangible Book Value | $143,535,000 | $-34,028,000 | $-12,064,000 | $75,120,000 |
| Invested Capital | $216,585,000 | $99,170,000 | $104,630,000 | $87,920,000 |
| Working Capital | $183,730,000 | $51,962,000 | $13,218,000 | $80,811,000 |
| Capital Lease Obligations | $1,278,000 | $792,000 | $999,000 | $1,323,000 |
| Total Capitalization | $216,585,000 | $99,170,000 | $66,930,000 | $87,920,000 |
| Treasury Stock | $10,983,000 | $10,983,000 | $10,983,000 | $7,536,000 |
| Additional Paid In Capital | $588,458,000 | $555,302,000 | $472,664,000 | $436,269,000 |
| Capital Stock | $6,000 | $5,000 | $4,000 | $3,000 |
| Common Stock | $6,000 | $5,000 | $4,000 | $3,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $859,000 | $372,000 | $456,000 | $843,000 |
| Current Capital Lease Obligation | $419,000 | $420,000 | $543,000 | $480,000 |
| Current Accrued Expenses | $9,120,000 | $12,381,000 | $14,416,000 | $2,558,000 |
| Investments And Advances | $47,879,000 | $6,010,000 | $0 | $20,000,000 |
| Available For Sale Securities | $47,879,000 | $6,010,000 | - | - |
| Goodwill | $4,701,000 | $4,701,000 | $4,701,000 | $0 |
| Net PPE | $1,701,000 | $1,013,000 | $1,526,000 | $1,782,000 |
| Accumulated Depreciation | $-314,000 | $-1,726,000 | $-1,634,000 | $-1,443,000 |
| Gross PPE | $2,015,000 | $2,739,000 | $3,160,000 | $3,225,000 |
| Leases | $139,000 | $710,000 | $710,000 | $710,000 |
| Other Properties | $1,215,000 | $1,128,000 | $1,650,000 | $1,949,000 |
| Machinery Furniture Equipment | $661,000 | $901,000 | $800,000 | $566,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $128,605,000 | $35,711,000 | $24,688,000 | $17,381,000 |
| Other Investments | - | - | - | $20,000,000 |
Fetched: 2026-06-01
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-2,433,000 | $-69,665,000 | $-33,831,000 | $-18,810,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-1,598,000 | $-69,665,000 | $-33,535,000 | $-18,717,000 |
| Cash Flow From Continuing Operating Activities | $-1,598,000 | $-69,665,000 | $-33,535,000 | $-18,717,000 |
| Operating Gains Losses | $-148,892,000 | $-1,620,000 | $57,000 | $-15,241,000 |
| Investing Activities | ||||
| Capital Expenditure | $-835,000 | - | $-296,000 | $-93,000 |
| Investing Cash Flow | $18,127,000 | $-22,161,000 | $-17,390,000 | $-36,719,000 |
| Cash Flow From Continuing Investing Activities | $18,127,000 | $-22,161,000 | $-17,390,000 | $-36,719,000 |
| Net Other Investing Changes | - | $-6,000,000 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,639,000 | $64,516,000 | $6,106,000 | $0 |
| Financing Cash Flow | $12,064,000 | $82,108,000 | $28,464,000 | $8,352,000 |
| Cash Flow From Continuing Financing Activities | $12,064,000 | $82,108,000 | $28,464,000 | $8,352,000 |
| Net Other Financing Charges | $-372,000 | $-1,440,000 | $692,000 | $-33,000 |
| Net Common Stock Issuance | $8,639,000 | $64,516,000 | $2,659,000 | $-4,723,000 |
| Common Stock Issuance | $8,639,000 | $64,516,000 | $6,106,000 | $0 |
| Repurchase Of Capital Stock | - | $0 | $-3,447,000 | $-4,723,000 |
| Other | ||||
| Repayment Of Debt | $0 | $-42,700,000 | $-17,536,000 | $-16,000 |
| Issuance Of Debt | $0 | $58,990,000 | $42,431,000 | $12,800,000 |
| Interest Paid Supplemental Data | $5,329,000 | $5,262,000 | $456,000 | $321,000 |
| End Cash Position | $62,406,000 | $33,785,000 | $43,049,000 | $65,466,000 |
| Beginning Cash Position | $33,785,000 | $43,049,000 | $65,466,000 | $112,346,000 |
| Effect Of Exchange Rate Changes | $28,000 | $454,000 | $44,000 | $204,000 |
| Changes In Cash | $28,593,000 | $-9,718,000 | $-22,461,000 | $-47,084,000 |
| Proceeds From Stock Option Exercised | $3,797,000 | $2,742,000 | $218,000 | $324,000 |
| Net Issuance Payments Of Debt | $0 | $16,290,000 | $24,895,000 | $12,784,000 |
| Net Long Term Debt Issuance | $0 | $16,290,000 | $24,895,000 | $12,784,000 |
| Long Term Debt Payments | $0 | $-42,700,000 | $-17,536,000 | $-16,000 |
| Long Term Debt Issuance | $0 | $58,990,000 | $42,431,000 | $12,800,000 |
| Net Investment Purchase And Sale | $18,514,000 | $-16,161,000 | $13,307,000 | $-22,536,000 |
| Sale Of Investment | $328,500,000 | $25,000,000 | $59,121,000 | $1,325,000 |
| Purchase Of Investment | $-309,986,000 | $-41,161,000 | $-45,814,000 | $-23,861,000 |
| Net PPE Purchase And Sale | $-387,000 | $0 | $-296,000 | $-93,000 |
| Sale Of PPE | $448,000 | $0 | - | - |
| Purchase Of PPE | $-835,000 | $0 | $-296,000 | $-93,000 |
| Change In Working Capital | $-26,512,000 | $-7,192,000 | $5,883,000 | $-406,000 |
| Change In Other Working Capital | $6,683,000 | $431,000 | $3,231,000 | $3,782,000 |
| Change In Other Current Liabilities | $-1,834,000 | $209,000 | $-79,000 | $-463,000 |
| Change In Other Current Assets | $451,000 | $0 | $321,000 | $663,000 |
| Change In Payables And Accrued Expense | $-15,587,000 | $-3,598,000 | $11,130,000 | $3,131,000 |
| Change In Prepaid Assets | $-2,943,000 | $-2,228,000 | $152,000 | $-894,000 |
| Change In Inventory | $-1,305,000 | $-8,874,000 | $206,000 | $147,000 |
| Change In Receivables | $-11,977,000 | $6,868,000 | $-9,078,000 | $-6,772,000 |
| Other Non Cash Items | $3,326,000 | $3,115,000 | $227,000 | $17,887,000 |
| Stock Based Compensation | $12,634,000 | $14,906,000 | $5,954,000 | $4,294,000 |
| Unrealized Gain Loss On Investment Securities | $-149,000 | $18,000 | $-613,000 | $577,000 |
| Provisionand Write Offof Assets | $11,681,000 | $5,746,000 | $0 | - |
| Asset Impairment Charge | $58,710,000 | $0 | - | - |
| Amortization Of Securities | $-3,128,000 | $-890,000 | $0 | - |
| Deferred Tax | $3,449,000 | $15,374,000 | $0 | - |
| Deferred Income Tax | $3,449,000 | $15,374,000 | $0 | - |
| Depreciation Amortization Depletion | $4,054,000 | $6,389,000 | $1,006,000 | $944,000 |
| Depreciation And Amortization | $4,054,000 | $6,389,000 | $1,006,000 | $944,000 |
| Gain Loss On Investment Securities | $-2,178,000 | $-2,057,000 | $98,000 | $-15,159,000 |
| Net Foreign Currency Exchange Gain Loss | $1,548,000 | $219,000 | $-198,000 | $-91,000 |
| Gain Loss On Sale Of PPE | $63,000 | $218,000 | $157,000 | $9,000 |
| Net Income From Continuing Operations | $83,229,000 | $-105,511,000 | $-46,049,000 | $-26,772,000 |
| Common Stock Payments | - | $0 | $-3,447,000 | $-4,723,000 |
| Net Business Purchase And Sale | - | $0 | $-30,401,000 | $-14,090,000 |
| Purchase Of Business | - | $0 | $-30,401,000 | $-14,090,000 |
| Net Short Term Debt Issuance | - | - | - | - |
| Short Term Debt Issuance | - | - | - | - |
Fetched: 2026-06-01